14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
ARTV vs MBIO: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Artiva Biotherapeutics, Inc. (ARTV) is the stronger overall head-to-head candidate over Mustang Bio, Inc. (MBIO) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). ARTV carries a Unified Composite Score of 48.5/100 (HOLD) at $3.96 (N/M Forward P/E, 0.0% operating margin), whereas MBIO carries 42.9/100 (HOLD) at $0.39 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: ARTV earns the overall head-to-head edge with a stronger Unified Composite Score (48.5/100 HOLD vs. MBIO 42.9/100 HOLD) and 1.70β · 116% Vol risk profile, whereas MBIO leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: ARTV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.2); meanwhile MBIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ARTV vs MBIO. Trailing 12-month operating profitability (ARTV 0.0% vs MBIO 0.0%) and valuation multiples (ARTV N/M vs MBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.2M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ARTV vs MBIO Key Questions & Quantitative Answers
As of Nov 17, 2026, Artiva Biotherapeutics, Inc. (ARTV) is the stronger overall head-to-head candidate over Mustang Bio, Inc. (MBIO) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). ARTV carries a Unified Composite Score of 48.5/100 (HOLD) at $3.96 (N/M Forward P/E, 0.0% operating margin), whereas MBIO carries 42.9/100 (HOLD) at $0.39 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: ARTV earns the overall head-to-head edge with a stronger Unified Composite Score (48.5/100 HOLD vs. MBIO 42.9/100 HOLD) and 1.70β · 116% Vol risk profile, whereas MBIO leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ARTV is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 22.2); meanwhile MBIO trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MBIO leads the Growth & Scale pillar: ARTV posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with MBIO at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ARTV generates N/A in USD-normalized revenue versus N/A for MBIO. In operating R&D and SG&A reinvestment, ARTV deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MBIO.
ARTV and MBIO trade at balanced relative valuation multiples. ARTV trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas MBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ARTV (-43.6% ROE) versus MBIO (-43.1% ROE) capital efficiency.
In options market volatility and institutional positioning, ARTV carries 53.6% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.37x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 116% Vol realized risk). By comparison, MBIO carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 87% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.